IL37 and myeloid sarcoma: Furthermore, recent studies in spinal cord injury (Coll-Miró et al., 2016; Amo-Aparicio et al., 2021) and in a mouse model of multiple sclerosis (MS) Cavalli et al., 2019; Sánchez-Fernández et al., 2021 have shown that IL-37 signaling has protective properties in two other neuroinflammatory models by both transgenic expression and recombinant delivery (Su and Tao, 2021).